Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients With Refractory Hyperlipidemia
Verve Therapeutics, Inc.
36 participants
Oct 30, 2024
INTERVENTIONAL
Conditions
Summary
VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.
Eligibility
Inclusion Criteria2
- Refractory hypercholesterolemia
- Refractory hypertriglyceridemia
Exclusion Criteria3
- Active or history of chronic liver disease
- Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe
- Clinically significant or abnormal laboratory values as defined by the protocol
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intravenous (IV) infusion
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06451770